Additionally, the 36-month beta value for GH is 1.44. There are mixed opinions on the stock, with 14 analysts rating it as a “buy,” 7 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
The public float for GH is 118.00M and currently, short sellers hold a 6.69% ratio of that float. The average trading volume of GH on March 19, 2025 was 2.36M shares.
GH) stock’s latest price update
Guardant Health Inc (NASDAQ: GH)’s stock price has gone rise by 2.91 in comparison to its previous close of 43.85, however, the company has experienced a 4.70% increase in its stock price over the last five trading days. seekingalpha.com reported 2025-03-13 that Guardant Health basically leads in liquid biopsy oncology diagnostics using genomic and digital technologies for early cancer detection. One of its main offerings is Guardant360, which is currently generating record revenues and growth for GH. Similarly, GH has an expanding pipeline, which includes its Reveal and Shield tests, that could significantly boost its future market potential.
GH’s Market Performance
Guardant Health Inc (GH) has seen a 4.70% rise in stock performance for the week, with a -6.51% decline in the past month and a 29.82% surge in the past quarter. The volatility ratio for the week is 6.22%, and the volatility levels for the past 30 days are at 7.65% for GH. The simple moving average for the last 20 days is 7.15% for GH’s stock, with a simple moving average of 40.37% for the last 200 days.
Analysts’ Opinion of GH
Many brokerage firms have already submitted their reports for GH stocks, with Barclays repeating the rating for GH by listing it as a “Overweight.” The predicted price for GH in the upcoming period, according to Barclays is $60 based on the research report published on January 23, 2025 of the current year 2025.
Guggenheim, on the other hand, stated in their research note that they expect to see GH reach a price target of $36. The rating they have provided for GH stocks is “Buy” according to the report published on June 28th, 2024.
Jefferies gave a rating of “Buy” to GH, setting the target price at $32 in the report published on June 03rd of the previous year.
GH Trading at 4.40% from the 50-Day Moving Average
After a stumble in the market that brought GH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -11.33% of loss for the given period.
Volatility was left at 7.65%, however, over the last 30 days, the volatility rate increased by 6.22%, as shares sank -8.18% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +33.26% upper at present.
During the last 5 trading sessions, GH rose by +4.39%, which changed the moving average for the period of 200-days by +63.78% in comparison to the 20-day moving average, which settled at $42.11. In addition, Guardant Health Inc saw 47.71% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at GH starting from Kalia Kumud, who sale 3,500 shares at the price of $43.16 back on Mar 17 ’25. After this action, Kalia Kumud now owns 19,720 shares of Guardant Health Inc, valued at $151,060 using the latest closing price.
Kalia Kumud, the Officer of Guardant Health Inc, proposed sale 3,500 shares at $43.16 during a trade that took place back on Mar 17 ’25, which means that Kalia Kumud is holding shares at $151,060 based on the most recent closing price.
Stock Fundamentals for GH
Current profitability levels for the company are sitting at:
- -0.6 for the present operating margin
- 0.61 for the gross margin
The net margin for Guardant Health Inc stands at -0.59. The total capital return value is set at -0.35. Equity return is now at value -4584.47, with -26.67 for asset returns.
Based on Guardant Health Inc (GH), the company’s capital structure generated 1.12 points at debt to capital in total, while cash flow to debt ratio is standing at -0.18. The debt to equity ratio resting at -9.57. The interest coverage ratio of the stock is -171.87.
Currently, EBITDA for the company is -390.12 million with net debt to EBITDA at -2.08. When we switch over and look at the enterprise to sales, we see a ratio of 8.61. The receivables turnover for the company is 6.7for trailing twelve months and the total asset turnover is 0.5. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.68.
Conclusion
In conclusion, Guardant Health Inc (GH) has seen better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
